Publisert 18.04.2019

Paragon Nordic AB - Collaboration

Paragon Nordic AB - Collaboration

Regenics AS, Oslo Norway has agreed a fee for service agreement with Paragon Nordic AB for development of a delivery format for HTX in a wound healing device. 

For more info, please contact Henrik Lund at henrik.lund@regenics.no or mobile +47 90971219

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.